CN1973867A - Chinese medicine prepn for treating arrhythmia - Google Patents
Chinese medicine prepn for treating arrhythmia Download PDFInfo
- Publication number
- CN1973867A CN1973867A CN 200610163234 CN200610163234A CN1973867A CN 1973867 A CN1973867 A CN 1973867A CN 200610163234 CN200610163234 CN 200610163234 CN 200610163234 A CN200610163234 A CN 200610163234A CN 1973867 A CN1973867 A CN 1973867A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- grams
- medicine preparation
- arrhythmia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 206010003119 arrhythmia Diseases 0.000 title abstract description 16
- 230000006793 arrhythmia Effects 0.000 title abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 210000000582 semen Anatomy 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 14
- 238000002156 mixing Methods 0.000 abstract description 7
- 229920001353 Dextrin Polymers 0.000 abstract description 6
- 239000004375 Dextrin Substances 0.000 abstract description 6
- 235000019425 dextrin Nutrition 0.000 abstract description 6
- 239000006071 cream Substances 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract 2
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 240000008866 Ziziphus nummularia Species 0.000 abstract 1
- -1 bolus Substances 0.000 abstract 1
- 238000002137 ultrasound extraction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 11
- 206010033557 Palpitations Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 208000001871 Tachycardia Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 206010003658 Atrial Fibrillation Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000006794 tachycardia Effects 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 230000009429 distress Effects 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 2
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 2
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 2
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 2
- 244000166550 Strophanthus gratus Species 0.000 description 2
- 206010049447 Tachyarrhythmia Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229940039750 aconitine Drugs 0.000 description 2
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
- 229960003343 ouabain Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000004124 rheumatic heart disease Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000008376 Pre-Excitation Syndromes Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003668 atrial tachycardia Diseases 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical class [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is one kind of arrhythmia treating Chinese medicine preparation and belongs to the field of Chinese medicine technology. The arrhythmia treating Chinese medicine preparation is prepared with nine kinds of Chinese medicinal materials including wild jujube seed, Chinese goldthread, schisandra, flavescent sophora root, fleeceflower root, etc. The preparation process includes water decoction, filtering and concentrating to obtain paste; adding dextrin into the paste and drying to obtain dry cream; ultrasonic extraction of the medicine residue, centrifuging and filtering the extracted liquid to obtain paste; mixing with the dry cream, adding dextrin, drying, crushing and further treatment to obtain medicine granule, bolus, capsule, tablet or mixture. The present invention has obtained treating effect.
Description
Technical field:
The invention belongs to the new Chinese medicine technical field, be specifically related to ARR Chinese medicine preparation of a kind of treatment and preparation method and its usage.
Background technology:
Arrhythmia is a common clinical disease, can or take medicine improper and other factors cause because of multiple heart disease.Though in motherland's medical literature, do not have ARR name of disease, in " interior warp ", had similar record.The Han dynasty Zhang Zhongjing has formally proposed the name of disease of cardiopalmus in " golden your outline ", two masterpieces of treatise on Febrile Diseases.It is meant patient's palpitation uneasiness, in addition fear so can not be autonomous a kind of disease.The general paroxysmal that is more, every because of fluctuation of feelings will or tired bringing out, with appearance such as caused arrhythmia of various heart diseases in the modern medicine and neurosis with cardiopalmus, to have palpitation be that the disease of primary symptom is similar.
Develop rapidly along with commodity economy, comprehensive infiltration of competition mechanism, the rhythm of the modern life is accelerated, increasing people is absorbed in the embarrassed look of psychentonia, overfatigue, further develop cardiopalmus, palpitation with a distress feeling, insomnia and dreamful sleep occur, easily wake up in sleeping, one's ears rang and spots danced before one's eyes, serious symptom such as forgetful, soreness of the waist and knees influences work in terror, can cause cerebral ischemia what is more and lead to heart infarction and apoplexy, the life and health of harm humans.
The generation of cardiopalmus early has argumentation in the TCM Document ancient books, the exopathogenic factor climate change, and the endogenous cause of ill damaged by excess of seven emotions all can cause the human body imbalance of YIN and YANG, and especially with deficiency of kidney-YIN, and the cardiopalmus due to the not good fire of water, disarmony between the heart and kidney for seeing more.The assertive evidence traditional Chinese medical science often adopts the wholistic therapy principle, with nourishing YIN and clearing away heat, restoring normal coordination between the heart and kidney, tranquilizing by nourishing the heart, hold back the method that the heart is throbbed with fear surely, selects the moon of nourishing the liver and kidney for use, and with the medicine of holding back heart and tranquilizing mind, Yin Yang balancing, make coordinating water and fire, Yi Daxin allay excitement peace, throb with fear normal pulse and usefulness.Base oneself upon theory of Chinese medical science, we propose the rule of treatment of " controlling from the moon opinion " through concentrating on studies for many years, reuse the method for nourishing YIN and supplementing blood.These sources of law are that fire is dirty in: the heart, and cloudy blood loses supports, or the not good heart of water, and heart-fire must be prosperous, and is intimately then aroused in interest, and the generation of " cardiopalmus " is arranged then.
A few class antiarrhythmic drugs that use clinically all exist common deficiency at present, as when treating arrhythmia, often bring out arrhythmia (incidence rate is up to more than 10%) again, also bring out conduction block and medicine source property heart failure simultaneously, and invalid to some intractable arrhythmia.
Summary of the invention:
Goal of the invention of the present invention is easily waken up in providing and a kind ofly treat cardiopalmus, palpitation with a distress feeling, insomnia and dreamful sleep due to disarmony between the heart and kidney, discordance between water and fire, the hyperactivity of fire caused by deficiency of YIN, sleeping, one's ears rang and spots danced before one's eyes, be called the Chinese medicine preparation of symptoms such as sinus arrhythmia, ectopic cardiac rhythm, active ectopic rhythm, various conduction block, pre-excitation syndrome and the preparation method and its usage of this Chinese medicine preparation in forgetful, soreness of the waist and knees or the modern medicine in terror.
The inventor utilizes modern crafts and preparation means to carry out systematization research, and under strong Basic Theories of Chinese Medicine is supported, develops the ARR Chinese medicine preparation of novel treatment.The preparation technology of this Chinese medicine preparation is simple, and production cost is lower, and loss of effective components is little, the yield rate height, and process route is stable, is easy to large-scale production.Prove that by quality standard research quality controllability is strong, the effective ingredient in the preparation is clear, and method of quality control is simple to operate, and stability and specificity are all stronger.
The object of the present invention is to provide the ARR Chinese medicine preparation of a kind of treatment, mainly make by following bulk drugs:
Semen Ziziphi Spinosae 30-40 part, Rhizoma Coptidis 4-8 part, Fructus Schisandrae Chinensis 28-35 part,
Radix Sophorae Flavescentis 8-15 part, Radix Polygoni Multiflori Preparata 28-35 part, Fructus Gardeniae 28-35 part,
Semen Platycladi 28-35 part, Herba Epimedii 28-35 part, Radix Glycyrrhizae Preparata 15-25 part.
Another object of the present invention is to be provided for treating the preparation method and the related dose forms thereof of ARR Chinese medicine preparation.
The ARR Chinese medicine preparation of treatment provided by the invention can obtain by the following method:
Above-mentioned nine flavors are got Rhizoma Coptidis, Radix Sophorae Flavescentis decocts with water three times.For the first time add 8 times of amounts, decocted 2 hours; For the second time add 6 times of amounts, decocted 1.5 hours; Add 6 times of amounts for the third time, decocted 1.5 hours; Filter, merging filtrate, being concentrated into relative density at 50 ℃ is 1.20～1.25 clear paste, standby; Get seven flavors such as all the other Semen Ziziphi Spinosaes and decoct with water three times, add 8 times of amounts for the first time, decocted 2 hours; For the second time add 6 times of amounts, decocted 2 hours; Add 6 times of amounts for the third time, decocted 1.5 hours; Filter, merging filtrate, being concentrated into relative density at 50 ℃ is 1.20～1.25 clear paste, merges with above-mentioned standby clear paste, it is an amount of to add dextrin, mixing, decompression is dried to dried cream at 75～80 ℃.
Above-mentioned medical material adopts ultrasonic extracting method to extract secondary.Amount of water is no less than 6 times for the first time, and amount of water must not be less than 5 times, merge extractive liquid, for the second time, centrifugal, filter, being concentrated into relative density at 50 ℃ is 1.20～1.25 clear paste, merges with above-mentioned standby clear paste, it is an amount of to add dextrin, mixing, decompression, vacuum drying, pulverize, get the extract of above-mentioned raw materials medical material.
On this basis, the present invention is prepared into satisfactory pharmaceutical preparation according to practice of pharmacy, comprises granule, pill, capsule, soft capsule, tablet, mixture etc., wherein contains Rhizoma Coptidis with berberine hydrochloride (C
20H
18CLNO
4) meter, must not be less than 10mg.
Matching and operability for after further reasonability, stability, repeatability and the amplification of these process conditions of checking are produced are quality standard research, stability study, pharmacological toxicology and clinical research sampling; And produce for further trial-production reference is provided, carried out trial production in three batches by above-mentioned process conditions, test agent was through the equal conformance with standard of quality control during the result showed, effective site content has reached the standard of new Chinese medicine the 6th class, every technological parameter is stable, reliable, good reproducibility, sample yield, content and the rate of transform all do not have than great fluctuation process, and three batches of pilot scale collimations are better.This process stabilizing is feasible, and eluting solvent environmental protection and cost are lower, meets the requirement of large-scale production.
The present invention treats ARR Chinese medicine preparation, is to be monarch drug with Semen Ziziphi Spinosae (stir-fry), Rhizoma Coptidis, the former YIN nourishing, latter's heat clearing away; Be ministerial drug with Radix Polygoni Multiflori Preparata, Fructus Schisandrae Chinensis, Radix Sophorae Flavescentis again, the principal drug assistance nourishing YIN and clearing away heat, coordinating water and fire, reach tranquilizing by nourishing the heart, hold back the effect that the heart is throbbed with fear surely; Be adjuvant with Fructus Gardeniae, Herba Epimedii, Semen Platycladi, Radix Glycyrrhizae Preparata again, both helped the monarch drug relieving restlessness of calming the nerves, again can warm venting QI-blood, in case the nourishing YIN-cold had, and loosening bowel to relieve constipation, make pathogenic heat by going down.All medicines are associated with, and eliminating heart-fire are arranged, the moon that nourishes heart, reinforcing the heart blood, mind calming god's effect, and than tradition side's medicine compatibility difference not only, and the effect that obtains is also more remarkable.
Creativeness of the present invention is first this Chinese medicine preparation to be used for the treatment of deficiency of kidney-YIN, the not good fire of water, palpitation with fear due to the disarmony between the heart and kidney, palpitation with a distress feeling, disease see insomnia and dreamful sleep, easily wake up in sleeping, one's ears rang and spots danced before one's eyes, forgetful, soreness of the waist and knees, the few tongue of red tongue, irregularly intermittent and regularly intermittent pulse or short etc. in terror.
In order to estimate this Chinese medicine preparation in the effect (main pharmacodynamics) aspect the arrhythmia, adopt the approach of irritating stomach, lumbar injection, intravenous administration with two dosage of 160mg/kg, 320mg/kg, designed five experiments altogether.The rat of bringing out for aconitine, the arrhythmia of domestic cat have been studied in experiment one, two, and the inhibitory action of this preparation has obviously been postponed aconitine and caused the time that arrhythmia occurs and shortened the ARR persistent period; The experiment three cat arrhythmia that proved electric stimulus inducing have the effect that improves its stimulation voltage threshold value; Experiment four is brought out in the Cavia porcellus arrhythmia at ouabain, and this preparation can improve the dosage of ouabain; Testing the rat ventricular that five pairs of barium chlorides bring out has preventive effect and can improve the effective percentage that arrhythmia is changeed multiple sinus rhythm.
Safety evaluatio is very important content in addition.The present invention has carried out general pharmacology and has learned and toxicologic study, and a system evaluation is made in the clinical preceding safety of medicine.
One, general pharmacology experiment
The said preparation that studies show that general pharmacology is learned has prevention and the ARR effect of antagonism, and to respiratory system and also not influence of central nervous system.
Two, anxious poison experiment
Chinese medicine toxicity for chemical drugs is lower, but it is nontoxic, low toxicity is relative, thereby strict reasonably toxicologic study is most important.Anxious poison experiment (maximum tolerated dose) at this Chinese medicine preparation shows mice lavage administration LD
50＞50g/kg, toxicity is lower, and this dosage is equivalent to 303 times of clinical daily oral dose (0.165g/kg), 455 times of one time oral dose.
Three, long poison experiment
With this Chinese medicine preparation little (1g/kg), in (3g/kg), big (9g/kg) three dosage irritate stomach respectively and give rat, this is equivalent to 6.1 times, 18.2 times, 54.4 times of clinical consumption per day, 18 times, 54.4 times, 163.6 times of people's one time oral dose.Be administered once every day, and successive administration 90 days is equivalent to three times an of course of treatment of clinical application (one month).Indexs such as ordinary circumstance, body weight, food ration, electrocardiogram, hematology and the blood biochemistry of observation rat, routine urinalysis, and in finish administration after 24 hours every group take out 10 and do pathological anatomy and observe, all the other animals continue to raise 2 week the back put to death and carry out pathological anatomy inspections.The result shows, tried little, in, the rat growthing development of big three dosage groups is good, do not find to cause dead and other toxic reaction because of drug intoxication.Liver function (SGPT), kidney merit (BUN) and hemogram are all in range of normal value, with matched group relatively there are no significant difference (P＞0.05).Other the half rat of respectively organizing after 2 weeks of drug withdrawal is put to death, the naked eyes no abnormality seen that becomes celestial, pathologic finding is the no abnormality seen pathological changes also.It is consistent to illustrate that each administration group rat is observed finding between administration and withdrawal time, does not see the delayed poisoning reaction, takes for a long time and does not also have the overt toxicity reaction.
The present invention is with the granule dosage form of this Chinese medicine preparation, specification is the 10g/ bag, boiled water is taken after mixing it with water, every day 3 times, each 1 bag, be one month usage and dosage the course of treatment, to clinical manifestation is tachyarrhythmia, and Chinese medical discrimination belongs to deficiency of kidney-YIN, the not good fire of water, palpitation with fear due to the disarmony between the heart and kidney, palpitation with a distress feeling patient carry out clinical application and observe (the severe arrhythmia person of being in peril of one's life out).
This organizes 40 people, male 21 people, women 19 people, the oldest 65 years old, minimum 22 years old, the elder of the course of disease 20 years, the shortest person 1 day, average course of disease 39.4.Atrial fibrillation 11 examples are wherein arranged, early rich person's 13 examples are arranged, tachycardia 16 examples are arranged.Be primary in coronary disease patient 23 examples, myocarditis person's 5 examples, hypertension patient's 4 examples, rheumatic heart disease 1 example, agnogenio person's 7 examples.
Clinical report, therapeutic effect see Table 1 and table 2:
All kinds of arrhythmia curative effect of table 1 table
| Sick classification | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Effectively total | |||||
| Example | ％ | Example | ％ | Example | ％ | Example | ％ | Example | ％ | ||
| Atrial fibrillation | 11 | 3 | 27.27 | 2 | 18.18 | 4 | 36.37 | 2 | 18.18 | 9 | 81.82 |
| Premature beat | 13 | 3 | 23.08 | 4 | 30.77 | 4 | 30.77 | 2 | 15.38 | 11 | 84.62 |
| Tachycardia | 16 | 5 | 31.25 | 3 | 18.75 | 5 | 31.25 | 3 | 18.75 | 13 | 81.25 |
| Amount to | 40 | 11 | 27.50 | 9 | 22.50 | 13 | 32.50 | 7 | 17.50 | 33 | 82.50 |
| P value atrial fibrillation and premature beat is P＞0.05 relatively; Atrial fibrillation and tachycardia be P＞0.05 relatively | |||||||||||
Classification of table 2 primary disease and curative effect table
| The protopathy classification | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Effectively total | |||||
| Example | ％ | Example | ％ | Example | ％ | Example | ％ | Example | ％ | ||
| Coronary heart disease | 23 | 5 | 21.74 | 6 | 26.09 | 9 | 39.13 | 3 | 13.04 | 20 | 88.96 |
| Myocarditis | 5 | 3 | 60.00 | 0 | - | 2 | 40.00 | 0 | - | 5 | 100 |
| Hypertension | 4 | 2 | 50.50 | 1 | 25.00 | 0 | - | 1 | 25.00 | 3 | 75.00 |
| Rheumatic heart disease | 1 | 0 | - | 1 | 100 | 0 | - | 0 | - | 1 | 100 |
| Other | 7 | 2 | 28.57 | 0 | - | 3 | 42.86 | 2 | 28.57 | 5 | 71.43 |
Table 1, table 2 result show, the present invention has better therapeutic effect to tachyarrhythmia, wherein the total effective rate of atrial fibrillation is 81.82%, early rich is 84.62%, and tachycardia is 81.25%, and the curative effect of atrial fibrillation is compared with rich, tachycardia early respectively, learn by statistics and handle the P value all greater than 0.05, illustrate that the present invention is approaching to the curative effect of all kinds of tachyarrhythmias, no significance difference, its total effective rate is 82.50%.
By to before and after patient's medication, blood pressure, breathing, blood, urine, the just observation of routine and liver, renal function have no significant change.Easily wake up to patient's insomnia and dreamful sleep, in sleeping, one's ears rang and spots danced before one's eyes, the improvement of forgetful, soreness of the waist and knees, the few tongue of red tongue, irregularly intermittent and regularly intermittent pulse or symptom such as short in terror, effect is highly significant also.
The present invention has comprised different dosage forms such as the granule that is prepared into according to practice of pharmacy, pill, capsule, soft capsule, tablet, mixture in the preparation of pharmaceutical preparation, overcome in traditional tcm therapy, can only decocting, take inconvenience, carry problems such as limited.
The specific embodiment:
Embodiment 1:
It is standby to get Semen Ziziphi Spinosae (stir-fry) 320 gram, Rhizoma Coptidis 50 grams, Fructus Schisandrae Chinensis 300 grams, Radix Sophorae Flavescentis 80 grams, Radix Polygoni Multiflori Preparata 300 grams, Fructus Gardeniae 330 grams, Semen Platycladi 330 grams, Herba Epimedii 320 grams, Radix Glycyrrhizae Preparata 180 grams;
Get Rhizoma Coptidis, Radix Sophorae Flavescentis decocts with water three times, for the first time adds 8 times of amounts, decocted 2 hours; For the second time add 6 times of amounts, decocted 1.5 hours; Add 6 times of amounts for the third time, decocted 1.5 hours; Filter, merging filtrate, at 50 ℃ of clear paste that are concentrated into relative density 1.20～1.25, standby; Get seven flavors such as all the other Semen Ziziphi Spinosaes and decoct with water three times, add 8 times of amounts for the first time, decocted 2 hours; For the second time add 6 times of amounts, decocted 2 hours; Add 6 times of amounts for the third time, decocted 1.5 hours; Filter, merging filtrate at 50 ℃ of clear paste that are concentrated into relative density 1.20～1.25, merges with above-mentioned standby clear paste, and the adding dextrin is an amount of, mixing, and decompression is dried to dried cream at 75～80 ℃.
Embodiment 2:
It is standby to get Semen Ziziphi Spinosae (stir-fry) 360 gram, Rhizoma Coptidis 60 grams, Fructus Schisandrae Chinensis 320 grams, Radix Sophorae Flavescentis 120 grams, Radix Polygoni Multiflori Preparata 320 grams, Fructus Gardeniae 300 grams, Semen Platycladi 300 grams, Herba Epimedii 300 grams, Radix Glycyrrhizae Preparata 200 grams;
Preparation method is identical with embodiment 1.
Embodiment 3:
It is standby to get Semen Ziziphi Spinosae (stir-fry) 64 gram, Rhizoma Coptidis 10 grams, Fructus Schisandrae Chinensis 30 grams, Radix Sophorae Flavescentis 16 grams, Radix Polygoni Multiflori Preparata 60 grams, Fructus Gardeniae 33 grams, Semen Platycladi 33 grams, Herba Epimedii 32 grams, Radix Glycyrrhizae Preparata 36 grams;
Above-mentioned medical material adopts ultrasonic extracting method to extract secondary.Amount of water is no less than 6 times for the first time, and amount of water must not be less than 5 times, merge extractive liquid, for the second time, centrifugal, filter, being concentrated into relative density at 50 ℃ is 1.20～1.25 clear paste, merges with above-mentioned standby clear paste, it is an amount of to add dextrin, mixing, decompression, vacuum drying, pulverize, get the extract of above-mentioned raw materials medical material.
Embodiment 4:
It is standby to get Semen Ziziphi Spinosae (stir-fry) 72 gram, Rhizoma Coptidis 12 grams, Fructus Schisandrae Chinensis 32 grams, Radix Sophorae Flavescentis 24 grams, Radix Polygoni Multiflori Preparata 64 grams, Fructus Gardeniae 30 grams, Semen Platycladi 30 grams, Herba Epimedii 30 grams, Radix Glycyrrhizae Preparata 40 grams;
Preparation method is identical with embodiment 3.
Embodiment 5:
Get raw medicinal material or its extract that embodiment 1 makes, it is an amount of to add lactose, is ground into fine powder, and mixing is used 60% alcohol granulation, and 75～80 ℃ of dryings, granulate is made 1000g, and packing promptly gets granule.This product contains Rhizoma Coptidis with berberine hydrochloride (C for every bag
20H
18CLNO
4) meter, must not be less than 10mg.[specification] 10g/ bag.
Embodiment 6:
Get raw medicinal material or its extract that embodiment 1 makes, add starch 180g and a small amount of micropowder silica gel, make 500g, encapsulated, make 1000.
Embodiment 7:
Get raw medicinal material or its extract that embodiment 1 makes, add 8 times of amounts of water, supersound extraction 30 minutes for the first time, add for the second time 6 times of amounts of water, supersound extraction 15 minutes, merge extractive liquid, filters, be concentrated into 800ml, centrifugal, use the 0.5um membrane filtration, get filtrate, add the preparation of an amount of refined honey and purified water, make 1000ml.
Claims (3)
1, the ARR Chinese medicine preparation of a kind of treatment, mainly make by the extract of following bulk drugs material or raw medicinal material:
Semen Ziziphi Spinosae 30-40 part, Rhizoma Coptidis 4-8 part, Fructus Schisandrae Chinensis 28-35 part,
Radix Sophorae Flavescentis 8-15 part, Radix Polygoni Multiflori Preparata 28-35 part, Fructus Gardeniae 28-35 part,
Semen Platycladi 28-35 part, Herba Epimedii 28-35 part, Radix Glycyrrhizae Preparata 15-25 part.
2, Chinese medicine preparation according to claim 1, its dosage form are granule or pill or capsule or soft capsule or tablet or mixture.
3, the application in preparation treatment antiarrhythmic medicament according to claim 1 or 2 described Chinese medicine preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610163234A CN100581566C (en) | 2006-12-13 | 2006-12-13 | Chinese medicine preparation for treating arrhythmia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610163234A CN100581566C (en) | 2006-12-13 | 2006-12-13 | Chinese medicine preparation for treating arrhythmia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1973867A true CN1973867A (en) | 2007-06-06 |
| CN100581566C CN100581566C (en) | 2010-01-20 |
Family
ID=38124401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610163234A Active CN100581566C (en) | 2006-12-13 | 2006-12-13 | Chinese medicine preparation for treating arrhythmia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100581566C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102698049A (en) * | 2012-06-15 | 2012-10-03 | 李良 | Crude rehmannia root Chinese medicinal decoction for treating palpitation and preparation method thereof |
| CN104127556A (en) * | 2014-08-14 | 2014-11-05 | 范恒银 | Traditional Chinese medicine (TCM) preparation for treating arrhythmia |
-
2006
- 2006-12-13 CN CN200610163234A patent/CN100581566C/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102698049A (en) * | 2012-06-15 | 2012-10-03 | 李良 | Crude rehmannia root Chinese medicinal decoction for treating palpitation and preparation method thereof |
| CN104127556A (en) * | 2014-08-14 | 2014-11-05 | 范恒银 | Traditional Chinese medicine (TCM) preparation for treating arrhythmia |
| CN104127556B (en) * | 2014-08-14 | 2016-04-27 | 范恒银 | One treats ARR Chinese medicine preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100581566C (en) | 2010-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103127305B (en) | Traditional Chinese medicine preparation with auxiliary protection function on alcoholic liver injury and preparation method thereof | |
| CN102626468B (en) | Traditional Chinese medicine combination for treating hepatitis B and preparing method and application thereof | |
| CN1058614C (en) | Galenic composition | |
| CN101461932B (en) | Medicament composition for treating children's damp-heat diarrhea induced by spleen insufficiency and preparation method thereof | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN101683423B (en) | Application of Chinese medicine composition in preparation of medicament for treating chicken pox | |
| CN100581566C (en) | Chinese medicine preparation for treating arrhythmia | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN102743646B (en) | Medicinal composition for inspecting and preventing diabetes | |
| CN102018852A (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN102631498B (en) | Chinese medicinal composition | |
| CN109091645A (en) | A kind of pharmaceutical composition with treatment inhibition of HIV | |
| CN1066064C (en) | Analgesic-antipyretic medicine and preparing method therefor | |
| CN1041494C (en) | Chinese-medicinal powder and capsule for treating chronic ischemic heart disease | |
| CN109125699A (en) | Application of the Xiao Chaihu Tang in preparation treatment hepatic encephalopathy drug | |
| CN102205049B (en) | Medicinal composition for treating premature beat | |
| CN101637533B (en) | Application of Chinese medicinal composition in preparation of medicament for treating virus myocarditis | |
| CN100515466C (en) | Chinese medicine preparation for treating stroke | |
| CN102631486B (en) | Health care composition | |
| CN102416147B (en) | Medicinal composition for treating mania of patients abstained from drugs | |
| CN1281223C (en) | Myocarditis treating medicine and its preparing process | |
| CN108261511A (en) | A kind of composition with antiobesity action and preparation method thereof and purposes | |
| CN101104033A (en) | Traditional Chinese medicinal preparation for treating Parkinson's disease and preparing process thereof | |
| CN1062844A (en) | Prevent and treat the preparation method of AIDS Chinese medicinal formulae | |
| CN103961429B (en) | Traditional Chinese medicine composition having effects of moving qi and invigorating blood circulation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Assignor: Gao Lu Contract record no.: 2012220000010 Denomination of invention: Arrhythmia treating Chinese medicine prepn and its prepn process Granted publication date: 20100120 License type: Exclusive License Open date: 20070606 Record date: 20120322 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Assignor: Gao Lu Contract record no.: 2012220000010 Date of cancellation: 20140314 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOP Effective date: 20140507 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140507 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee after: Gao Lu Patentee after: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Patentee after: Liaoning revised Biological Pharmaceutical Co Ltd Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee before: Gao Lu |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151009 Address after: 130103, Shunda road 1369, hi tech Zone, Jilin, Changchun Patentee after: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Patentee after: Liaoning revised Biological Pharmaceutical Co Ltd Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee before: Gao Lu Patentee before: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Patentee before: Liaoning revised Biological Pharmaceutical Co Ltd |